Ari Green, MD

Dr. Green, Chief of the Division of Neuroinflammation and Glial Biology at the University of California, San Francisco, discusses the development of potential remyelinating therapies and a recent trial of clemastine fumarate in patients with multiple sclerosis and chronic demyelinating optic neuropathy.


Next Article:

High Dose of Novel Compound Shows Promise for Relapsing-Remitting MS

Related Articles